DE2912112C2 - Antikrebs-Präparat - Google Patents

Antikrebs-Präparat

Info

Publication number
DE2912112C2
DE2912112C2 DE2912112A DE2912112A DE2912112C2 DE 2912112 C2 DE2912112 C2 DE 2912112C2 DE 2912112 A DE2912112 A DE 2912112A DE 2912112 A DE2912112 A DE 2912112A DE 2912112 C2 DE2912112 C2 DE 2912112C2
Authority
DE
Germany
Prior art keywords
fluorouracil
uracil
preparation
cancer
connection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2912112A
Other languages
German (de)
English (en)
Other versions
DE2912112A1 (de
Inventor
Setsuro Toyonaka Osaka Fujii
Setsuo Tokushima Takeda
Norio Unemi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP3583478A external-priority patent/JPS54129131A/ja
Priority claimed from JP9281378A external-priority patent/JPS5519245A/ja
Priority claimed from JP13768678A external-priority patent/JPS5564518A/ja
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of DE2912112A1 publication Critical patent/DE2912112A1/de
Application granted granted Critical
Publication of DE2912112C2 publication Critical patent/DE2912112C2/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE2912112A 1978-03-27 1979-03-27 Antikrebs-Präparat Expired DE2912112C2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP3583478A JPS54129131A (en) 1978-03-27 1978-03-27 Antiimalignant tumor agent composition
JP9281378A JPS5519245A (en) 1978-07-28 1978-07-28 Anti-malignant tumor agent composition
JP13768678A JPS5564518A (en) 1978-11-07 1978-11-07 Carcinostatic composition

Publications (2)

Publication Number Publication Date
DE2912112A1 DE2912112A1 (de) 1979-10-11
DE2912112C2 true DE2912112C2 (de) 1983-05-26

Family

ID=27288895

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2912112A Expired DE2912112C2 (de) 1978-03-27 1979-03-27 Antikrebs-Präparat

Country Status (6)

Country Link
US (2) US4650801A (it)
CH (1) CH639274A5 (it)
DE (1) DE2912112C2 (it)
FR (1) FR2420974A1 (it)
GB (1) GB2016921B (it)
IT (1) IT1119283B (it)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59083A (en) * 1979-01-10 1983-12-30 Israel Marcus Pharmaceutical composition containing thymidine and a salicyclic acid derivative as a solubilizing agent therefor
JPS5735516A (en) * 1980-08-11 1982-02-26 Yamasa Shoyu Co Ltd Agent for increasing radiosensitivity or agent for increasing effect of substance having activity similar to radiation
AU548712B2 (en) * 1983-05-23 1986-01-02 Taiho Pharmaceutical Co., Ltd. 2:-deoxy-5-substituted uridine derivatives
US4864021A (en) * 1984-10-30 1989-09-05 Otsuka Pharmaceutical Co., Ltd. 5-fluorouracil derivatives
NL8700366A (nl) * 1987-02-13 1988-09-01 Stichting Rega V Z W Combinatie van fu met bvdu als middel tegen adenocarcinoom.
DK0500953T3 (da) * 1990-09-07 1997-01-06 Taiho Pharmaceutical Co Ltd Potentiator af antineoplastisk virkning og antineoplastisk middel
WO1999008686A1 (en) * 1997-08-21 1999-02-25 Basf Aktiengesellschaft Use of uridine to counter 5-fluorouracil toxicity
JPH11116564A (ja) * 1997-10-09 1999-04-27 Otsuka Chem Co Ltd クロモン誘導体
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US20030134003A1 (en) * 2001-10-09 2003-07-17 Medigreen Biotechnology Inc. Method of using geranium oil and sophora root extracts as a supporting composition in cancer treatments
CN102014900B (zh) * 2008-03-11 2014-04-02 大学健康网络 一种神经肽y5r(npy5r)拮抗剂在制备治疗癌症的药物中的应用
ITMI20120921A1 (it) 2012-05-28 2013-11-29 Fond Istituto Italiano Di Tec Nologia 45 Inibitori della ceramidasi acida e loro usi come medicamenti

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU523746B2 (en) * 1977-04-05 1982-08-12 Taiho Pharmaceutical Co., Ltd. Anticancer composition
US4481203A (en) * 1977-04-05 1984-11-06 Taiho Pharmaceutical Company, Limited Composition containing 1-(n-hexylcarbamoyl)-5-fluorouracil and uracil
US4328229A (en) * 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
JPS5735516A (en) * 1980-08-11 1982-02-26 Yamasa Shoyu Co Ltd Agent for increasing radiosensitivity or agent for increasing effect of substance having activity similar to radiation
JPS5767518A (en) * 1980-09-17 1982-04-24 Yamasa Shoyu Co Ltd Radiosensitizing agent or agent for increasing effect of radiomimetic substance

Also Published As

Publication number Publication date
GB2016921A (en) 1979-10-03
CH639274A5 (de) 1983-11-15
US4650801A (en) 1987-03-17
US4914105A (en) 1990-04-03
GB2016921B (en) 1982-08-18
DE2912112A1 (de) 1979-10-11
IT1119283B (it) 1986-03-10
IT7967629A0 (it) 1979-03-27
FR2420974A1 (fr) 1979-10-26
FR2420974B1 (it) 1983-06-24

Similar Documents

Publication Publication Date Title
DE2455423C3 (de) 28.11.73 Japan 132796-73 26.04.74 Japan 46617-74 In 1-Stellung acylierte 5-Fluoruracile und Arzneimittel aus diesen Verbindungen und üblichen inerten Bindemitteln oder Trägermaterialien
DE2912112C2 (de) Antikrebs-Präparat
DE2756653C2 (de) 5'-Deoxy-5-fluorcytidin und 5'- Deoxy-5-fluoruridin, deren Isopropylidenderivate und Salze und Verfahren zu deren Herstellung
DE2915254A1 (de) Neue chemische verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel mit antiviraler wirkung
DD284679A5 (de) Verfahren zur herstellung von adenosin 5'-carboamidderivate
DE2528360A1 (de) Neue pyrimidine, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen
DE2056327A1 (de) Aminopunn Derivate
DE2923368A1 (de) Neue 5-fluor-( beta -uridin oder 2'-desoxy- beta -uridin)-derivate, verfahren zur herstellung derselben und carcinostatische mittel mit einem gehalt derselben
DE2530416A1 (de) Alkylaminoglucopyranosid-derivate und verfahren zu ihrer herstellung
AT391864B (de) Verfahren zur herstellung von neuen 5-pyrimidincarboxamiden und deren additionssalzen
DE2119964C3 (de) Methyl N (N5 methyl N1 nitroso carbamoyiyD glycosaminid und Ver fahren zu dessen Herstellung
DE2739912A1 (de) Uracilderivate und herstellungsverfahren
DE2639135C2 (de) 1-Alkylcarbamoyl-5-Fluoruracil-Derivate, ihre Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DE69907161T2 (de) 5' deoxycytidin-derivative
DE2814202C2 (de) Verwendung von Uracilderivaten zur Bekämpfung von Krebs oder krebsartigen Erkrankungen
DE2059358A1 (de) Pyridon- und Thiopyridonderivate,die als entzuendungshemmende Mittel geeignet sind
DE3588103T2 (de) 5-Fluorouracil-Derivate
CH643830A5 (de) Bis-moranolin-derivate.
EP0256400A2 (de) Pyrimidinderivate, ihre Herstellung und Medikamente die diese Derivate enthalten
DE2633359C3 (de) 5-Fluorpyrimidin-4-on-Derivateenthaltende Antitumormittel
DE3820588C2 (it)
DE69019807T2 (de) Pyrimidindionderivate, Verfahren zu deren Herstellung und diese enthaltende antiarrhythmische Mittel.
DE2817923C2 (de) Septacidinverbindungen und diese enthaltende Arzneimittel
DE2723450A1 (de) Uracilderivate und verfahren zu ihrer herstellung
DE3709699C2 (de) 5-Fluoruracil-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung

Legal Events

Date Code Title Description
OAP Request for examination filed
OD Request for examination
8181 Inventor (new situation)

Free format text: FUJII, SETSURO, TOYONAKA, OSAKA, JP UNEMI, NORIO TAKEDA, SETSUO, TOKUSHIMA, JP

D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee